Belzutifan for Recurrent Clear Cell Gynecologic Cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a daily pill called belzutifan for people with a rare type of gynecologic cancer (clear cell carcinoma) that has come back or not gone away after standard treatments. The drug works by targeting a protein that helps tumors grow when oxygen levels are low.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of gynecologic cancer that is mostly clear cell (ovarian, endometrial, cervical, or related).
- You have already received at least one round of chemotherapy that included a platinum drug (like carboplatin or cisplatin).
- Your cancer has come back or continues to grow despite prior treatment.
- You are able to swallow pills and have adequate liver, kidney, and blood function as determined by standard tests.
- You have not taken belzutifan or a similar drug before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called dostarlimab alone or with bevacizumab compared to standard chemotherapy for women whose clear cell cancer of the ovary, uterus, cervix, vagina, or vulva has come back within a year of platinum chemotherapy. The goal is to see if these newer treatments can help control the cancer better.
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
This study tests a new drug called raludotatug deruxtecan for people with ovarian cancer that has come back. It's designed for those whose cancer is either sensitive or resistant to platinum chemotherapy, and who have had 1-3 prior treatments.
This trial tests an oral drug called belzutifan in adolescents with specific types of solid tumors, such as pheochromocytoma/paraganglioma, wild-type gastrointestinal stromal tumors, or tumors linked to von Hippel-Lindau disease. It aims to see if the drug can shrink or control these tumors.
This trial tests a new drug called belzutifan combined with a special imaging agent (89Zr-DFO-girentuximab) to see how they affect PET scans in people with advanced clear cell kidney cancer. It may help doctors better understand the cancer and guide treatment.
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.